If those predictions are correct, AZ’s oral PCSK9 could have to contend with cut-price antibody drugs, a long-acting siRNA benefiting from marketing alongside Novartis’ blockbuster heart ...

The category of genetic medicine for cardiovascular disease based on siRNA and antisense oligonucleotides ... the pack with Leqvio (inclisiran), its PCSK9-targeting antisense drug for reducing ...